A Randomized, Double-Blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination with Azacitidine or Decitabine in the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Description: 
To compare overall survival (OS) between treatment arms.
Study Number: 

PH 282116

Phase: 
3
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02785900

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.